Abstract
Dear Editor, We read with great interest the article by Cohen and Felix ( 1 ) concerning reimbursement restrictions on orphan drugs. We agree with their concerns that orphan drugs are often met with reimbursement restrictions, but data on the relationship between orphan status and pricing and reimbursement outcomes are scarce. Furthermore, regional disparities within Europe are likely to be significant, contributing to the previously reported heterogeneous uptake across different countries ( 2 ). (Published: 9 December 2014) Citation: Journal of Market Access & Health Policy 2014, 2 : 25925 - http://dx.doi.org/10.3402/jmahp.v2.25925
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
